8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 27, 2019

Supernus Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of
Incorporation)

001-35518	20-2590184
(Commission File Number)	(IRS Employer Identification No.)
1550 East Gude Drive, Rockville MD	20850
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code:  (301) 838-2500

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 8.01              Other Events.

On March 27, 2019, Supernus Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that the Company will issue a press release and host a conference call on March 28, 2019, to discuss the topline results of its final Phase III study for SPN-812 in patients 12-17 years old (P304) for the treatment of attention deficit hyperactivity disorder (“ADHD”).  A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

On March 28, 2019, the Company issued a press release announcing topline results from its P304 study for the treatment of ADHD in patients 12-17 years old, which is the Company’s fourth clinical trial in the SPN-812 Phase III program.  A copy of this press release is furnished as Exhibit 99.2 hereto and is incorporated herein by reference.

Item 9.01              Financial Statements and Exhibits.

(d)           Exhibit

The following document is furnished as an Exhibit pursuant to Item 8.01 hereof:

Exhibit 99.1 — Press Release Dated March 27, 2019.

Exhibit 99.2 — Press Release Dated March 28, 2019.

Exhibit 99.3 — Presentation Slides.

2

EXHIBIT INDEX

Number	Description
99.1	Press Release Dated March 27, 2019.	Attached
99.2	Press Release Dated March 28, 2019.	Attached
99.3	Presentation Slides.	Attached

3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SUPERNUS PHARMACEUTICALS, INC.
DATED: March 28, 2019	By:	/s/ Gregory S. Patrick
		Gregory S. Patrick
		Senior Vice President and Chief Financial Officer

4

EX-99.1

Exhibit 99.1

Supernus Hosts Conference Call to Present Topline Results of Final

Phase III Study for SPN-812 in Adolescents with ADHD

ROCKVILLE, Md., March 27, 2019 — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that, on Thursday, March 28, 2019, at approximately 8:00 a.m. ET, it will issue a press release announcing the results of its final Phase III study for SPN-812 in patients 12-17 years old (P304) for the treatment of attention deficit hyperactivity disorder (ADHD).

Supernus will hold a conference call and webcast on Thursday, March 28, 2019, at 9:00 a.m. ET to discuss the topline results of the clinical trial. Presentation slides will be made available approximately 30 minutes prior to the call. The call will be hosted by Jack Khattar, President and Chief Executive Officer; Stefan Schwabe, Chief Medical Officer and Executive Vice President of Research & Development; and Greg Patrick, Senior Vice President and Chief Financial Officer.

Conference Call Details

Presentation slides will be available via this webcast link approximately 30 minutes prior to the conference and webcast. A question and answer session with the Supernus management team will follow the Company’s remarks.

Please refer to the information below for conference call dial-in information and webcast registration. Callers should dial in approximately 10 minutes prior to the start of the call.

Conference dial-in:             (877) 288-1043

International dial-in:           (970) 315-0267

Conference ID:                    9278115

Conference Call Name:       Supernus Pharmaceuticals SPN-812 Phase III Topline Results

Webcast link:                       Click here

Following the live call, a replay will be available on the company’s website, www.supernus.com, under ‘Investors Relations’.

About SPN-812

SPN-812 is a serotonin norepinephrine modulating agent (SNMA) that Supernus is developing as a novel non-stimulant for the treatment of ADHD. Based on data generated to date, the Company believes SPN-812 could be a well-differentiated ADHD treatment compared to other non-stimulant treatments for ADHD due to its different pharmacological and pharmacokinetic profile. The active ingredient in SPN-812, viloxazine hydrochloride, has an extensive safety record in Europe, where it was previously marketed for many years as an antidepressant.

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company currently markets Trokendi XR® (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy, and Oxtellar XR® (extended-release oxcarbazepine) for the treatment of epilepsy. The Company is also developing several product candidates to address large market opportunities in psychiatry, including SPN-810 for the treatment of Impulsive Aggression in ADHD patients, SPN-812 for the treatment of ADHD and SPN-604 for the treatment of bipolar disorder.

Forward-Looking Statements:

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not convey historical information, but relate to predicted or potential future events that are based upon management’s current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the Company’s ability to sustain and increase its profitability; the Company’s ability to raise sufficient capital to fully implement its corporate strategy; the implementation of the Company’s corporate strategy; the Company’s future financial performance and projected expenditures; the Company’s ability to increase the number of prescriptions written for each of its products; the Company’s ability to increase its net revenue; the Company’s ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; the Company’s product research and development activities, including the timing and progress of the Company’s clinical trials, and projected expenditures; the Company’s ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company’s product candidates; the Company’s ability to protect its intellectual property and operate its business without infringing upon the intellectual property rights of others; the Company’s expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits, effectiveness and safety of the Company’s product candidates; the accuracy of the Company’s estimates of the size and characteristics of the markets that may be addressed by its product candidates; the Company’s ability to increase its manufacturing capabilities for its

products and product candidates; the Company’s projected markets and growth in markets; the Company’s product formulations and patient needs and potential funding sources; the Company’s staffing needs; and other risk factors set forth from time to time in the Company’s filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. The Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events.

CONTACT:

Jack A. Khattar, President and CEO

Gregory S. Patrick, Vice President and CFO

Supernus Pharmaceuticals, Inc.

Tel: (301) 838-2591

Or

Investor Contact:

Peter Vozzo

Westwicke Partners

Office: (443) 213-0505

Mobile: (443) 377-4767

Email: peter.vozzo@westwicke.com

EX-99.2

Exhibit 99.2

Supernus Announces P304 Phase III Data Confirming Positive Results from Previous Three Phase III Studies on SPN-812 in ADHD

·400 mg dose reached statistical significance compared to placebo, consistent with previous Phase III studies:

·Change versus baseline in ADHD Rating Scale 5, p-value = 0.0082

·Effect size of 0.66

·CGI-I secondary endpoint, p-value = 0.0051

·Hyperactivity/Impulsivity subscale, p-value = 0.0484

·Inattention subscale, p-value = 0.0042

·600 mg dose narrowly missed statistical significance with p-value = 0.0712

·SPN-812 was well-tolerated with low incidence of adverse events and low discontinuation rates consistent with previous Phase III studies

·Complete Phase III program consists of robust Phase III data on 100 mg, 200 mg, and 400 mg doses in more than 1,000 patients with supporting data from two Phase II studies

·New Drug Application (NDA) continues to be on track for 2H 2019 submission

ROCKVILLE, Md., March 28, 2019 — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced topline results from the second Phase III study of SPN-812 in adolescents (P304) for the treatment of attention deficit hyperactivity disorder (ADHD) .

P304 is the fourth clinical trial in the SPN-812 Phase III program. Positive data from three successful pivotal trials (P301, P302, and P303) were reported in December 2018.

“We are pleased with the final data confirming the positive results we announced in the previous Phase III studies on SPN-812 last year in December. We now have robust data on 100 mg, 200 mg and 400 mg doses from all four Phase III clinical trials with SPN-812 in patients with ADHD. The data are consistent in showing a clinically meaningful reduction in the symptoms of ADHD, with a favorable safety and tolerability profile,” stated Jack Khattar, President and Chief Executive Officer of Supernus Pharmaceuticals. “We are focused on putting the NDA together for submission in the second half of this year.”

About the P304 Phase III Study

The study is a randomized, double-blind, placebo controlled, multicenter, parallel group clinical trial in adolescents 12 to 17 years of age diagnosed with ADHD. Each treatment was administered orally once a day over seven weeks, including one week of titration for 400 mg and two weeks of titration for 600 mg.

A total of 297 patients were randomized across placebo and two doses of SPN-812 (400 mg/600 mg). The primary objective was to assess the effect of SPN-812 in reducing the symptoms of ADHD in adolescents 12-17 years old. The primary outcome measure was the change from baseline to the end of the study in the ADHD-RS-5 total score tested on the 600 mg followed by the 400 mg in the statistical plan. Safety and tolerability of SPN-812 were assessed by the monitoring of adverse events (AEs), clinical laboratory tests, vital signs, ECGs, suicidality and physical examinations. Patients who completed the study were offered the opportunity to continue into an open-label phase that is currently on-going.

P304 Phase III Topline Results

At the end of the study (EOS), SPN-812 400 mg reached statistical significance compared to placebo in the primary endpoint. Patients receiving SPN-812 400 mg had an -18.3 LS Mean change from baseline (p=0.0082) vs. LS Mean change of-13.2 from baseline for placebo at week 7. With respect to SPN-812 600 mg, the LS Mean change of -16.7 (p=0.0712) from baseline in the primary endpoint was observed at week 7.

The result, based on Mixed Model Repeated Measures (MMRM) analysis in the Intent-To-Treat (ITT) population, was consistent with the results from sensitivity analyses using Analysis of Covariance (ANCOVA) (400 mg, p=0.0191; 600 mg, p=0.1002) at week 7 (EOS) with placebo based imputation for missing data.

At the 400 mg dose, SPN-812 demonstrated statistically significant onset of action starting week 2 (p=0.0063), which continued to the end of study at week 7 (p=0.0082). At 600 mg dose, SPN-812 demonstrated statistically significant difference from placebo in the primary endpoint during the last week of titration (week 2 dosed at 400 mg, p=0.0456) and the first week of maintenance (week 3 dosed at 600 mg, p=0.0238).

Similar to the first three studies (P301, P302 and P303), at the end of the P304 study, SPN-812 400 mg reached statistical significance compared to placebo on the hyperactivity/impulsivity and inattention subscales of the ADHD-RS-5 scale with p-values of 0.0484 and 0.0042, respectively.

In addition, SPN-812 400 mg dose met the Clinical Global Impression-Improvement secondary endpoint with p-value of 0.0051 compared to placebo.

While the 600 mg dose did not reach statistical significance, it is not needed for the submission or approvability of the NDA for children and adolescents. It was included to check for a potentially higher level of efficacy, to help in identifying the maximum effective dose, and to help in designing our trials for the adult population.

Overall, the trial exhibited favorable tolerability and safety profiles consistent with the other Phase III trials with low incidence of AEs across all doses. AEs were mild leading to low discontinuation rates of 4.0% to 5.1%. Treatment related AEs that reported at more than or equal to 5% for SPN-812 were somnolence, fatigue, decreased appetite, headache and nausea.

“In addition to the consistent and clinically meaningful efficacy data, we continue to be encouraged by the safety and tolerability of SPN-812 especially that the 600 mg dose showed a similar profile to the 400 mg dose. We believe this compelling safety profile at a wide range of doses should provide physicians with dosing flexibility,” stated Dr. Stefan Schwabe, Executive Vice President R&D and Chief Medical Officer of Supernus Pharmaceuticals.

With the completion of the P304 study, the Company now has a robust clinical data package in more than 1,000 children and adolescent patients across all three doses of SPN-812: 100 mg, 200 mg and 400 mg. The Company continues to be focused on putting together the NDA for submission to the Food and Drug Administration in the second half of this year.

Conference Call Details

The Company will hold a conference call and webcast today, March 28, 2019, at 9:00 a.m. ET to discuss these topline results. The call will be hosted by Jack Khattar, President and Chief Executive Officer, Dr. Stefan Schwabe, Executive Vice President R&D and Chief Medical Officer, and Greg Patrick, Vice President and Chief Financial Officer. Presentation slides will be available via this webcast link approximately 30 minutes prior to the call. A question and answer session with the Supernus management team will follow the company’s remarks.

Please refer to the information below for conference call dial-in information and webcast registration. Callers should dial in approximately 10 minutes prior to the start of the call.

Conference dial-in:	(877) 288-1043
International dial-in:	(970) 315-0267
Conference ID:	9278115
Conference Call Name:	Supernus Pharmaceuticals SPN-812 Phase III Topline Results
Webcast link:	Click here

Following the live call, a replay will be available on the company’s website, www.supernus.com, under ‘Investors Relations’.

About SPN-812

SPN-812 is a serotonin norepinephrine modulating agent (SNMA) that Supernus is developing as a novel non-stimulant for the treatment of ADHD. Based on data generated to date, the Company believes SPN-812 could be a well-differentiated ADHD treatment compared to other non-stimulant treatments for ADHD due to its different pharmacological and pharmacokinetic profile. The active ingredient in SPN-812, viloxazine hydrochloride, has an extensive safety record in Europe, where it was previously marketed for many years as an antidepressant.

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company currently markets Trokendi XR® (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy, and Oxtellar XR® (extended-release oxcarbazepine) for the treatment of epilepsy. The Company is also developing several product candidates to address large market opportunities in psychiatry, including SPN-810 for the treatment of Impulsive Aggression in ADHD patients, SPN-812 for the treatment of ADHD and SPN-604 for the treatment of bipolar disorder.

Forward-Looking Statements:

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not convey historical information, but relate to predicted or potential future events that are based upon management’s current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the Company’s ability to successfully complete the development of its product candidates including SPN-812, obtain regulatory approval and commercially market them; the Company’s ability to sustain and increase its profitability; the Company’s ability to raise sufficient capital to fully implement its corporate strategy; the implementation of the Company’s corporate strategy; the Company’s future financial performance and projected expenditures; the Company’s ability to increase the number of prescriptions written for each of its products; the Company’s ability to increase its net revenue; the Company’s ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; the Company’s product research and development activities, including the timing and progress of the Company’s clinical trials, and projected expenditures; the Company’s ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company’s product candidates; the Company’s ability to protect its intellectual property and operate its business without infringing upon the intellectual property rights of others; the Company’s expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits,

effectiveness and safety of the Company’s product candidates; the accuracy of the Company’s estimates of the size and characteristics of the markets that may be addressed by its product candidates; the Company’s ability to increase its manufacturing capabilities for its products and product candidates; the Company’s projected markets and growth in markets; the Company’s product formulations and patient needs and potential funding sources; the Company’s staffing needs; and other risk factors set forth from time to time in the Company’s filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. The Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events.

CONTACT:

Jack A. Khattar, President and CEO

Gregory S. Patrick, Vice President and CFO

Supernus Pharmaceuticals, Inc.

Tel: (301) 838-2591

Or

Investor Contact:

Peter Vozzo

Westwicke Partners

Office: (443) 213-0505

Mobile: (443) 377-4767

Email: peter.vozzo@westwicke.com

EX-99.3

Exhibit 99.3

1 Supernus Pharmaceuticals SPN-812 P304 Phase III Topline Data March 28, 2019

Safe Harbor Statement This presentation includes forward-looking statements within the meaning of the federal securities laws. These statements, among other things, relate to Supernus’ business strategy, goals and expectations concerning its product candidates, future operations, prospects, plans and objectives of management. The words “anticipate”, “believe”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict“, “project”, “will“, and similar terms and phrases are used to identify forward-looking statements in this presentation. Supernus’ operations involve risks and uncertainties, many of which are outside its control, and any one of which, or a combination of which, could materially affect its results of operations and whether the forward-looking statements ultimately prove to be correct. Supernus assumes no obligation to update any forward-looking statements except as required by applicable law. Supernus has filed with the U.S. Securities and Exchange Commission (SEC) reports and other documents required by Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. Before you purchase any Supernus securities, you should read such reports and other documents to obtain more complete information about the company’s operations and business and the risks and uncertainties that it faces in implementing its business plan. You may get these documents for free by visiting EDGAR on the SEC website at http://www.sec.gov. 2

Viloxazine hydrochloride Serotonin norepinephrine modulating agent (SNMA) New Chemical Entity (NCE) with five year market exclusivity Previously marketed outside the U.S. as an antidepressant Building strong IP with expirations from 2029-2033 Clinical data point to a well-differentiated ADHD product Continue to target NDA submission 2H 2019, and if approved, launch 2H 2020 3 SPN-812 Novel Non-Stimulant ADHD Product Candidate

SPN-812 Phase III Studies Status P301 N = 477 P303 N = 313 P302 N = 310 P304 N = 297 ADHD Patients 6-11 years 6-11 years 12-17 years 12-17 years Daily Doses 100 mg 200 mg 200 mg 400 mg 200 mg 400 mg 400 mg 600 mg Status Completed Completed Completed Completed 4

SPN-812 P304 Phase III Study Design Monotherapy in adolescent ADHD patients 12-17 years old Primary Endpoint Change from baseline on ADHD-RS-5 scale compared to placebo Secondary Endpoints Clinical Global Impression - Improvement (CGI-I) scale Conners 3rd Edition - parent, composite T-score Weiss Functional Impairment Rating Scale - parent report (WFIRS-P) Evaluate safety & tolerability 5

SPN-812 P304 Topline Results Executive Summary Data confirm positive results from P301, P302, and P303 Phase III studies 400 mg reached statistical significance on: Change versus baseline in ADHD Rating Scale 5, p-value = 0.0082 Effect size of 0.66 CGI-I secondary endpoint, p-value = 0.0051 Hyperactivity/Impulsivity subscale, p-value = 0.0484 Inattention subscale, p-value = 0.0042 Sensitivity analysis confirms primary analysis 6

SPN-812 P304 Topline Results Executive Summary Data confirm positive results from P301, P302, and P303 Phase III studies 400 mg shows fast onset of action Statistical significance as early as 2 weeks Higher dose of 600 mg did not reach statistical significance Narrowly missed on primary endpoint with p-value of 0.0712 May indicate a dosage plateauing effect Not needed for approvability of NDA Consistent favorable tolerability and safety profile Low incidence of AE’s across both doses (400 mg and 600 mg) Low discontinuation rates due to AE’s of 4.0% - 5.1% 7

SPN-812 P304 Phase III Topline Results Visit Statistics Placebo (N=96) 400 mg (N=99) 600 mg (N=97) Baseline Mean 38.8 41.2 39.8 Week 7 (EOS) LS Mean -13.2 -18.3 -16.7 p-value 0.0082 0.0712 8 MMRM = Mixed Model for Repeated Measure ITT = Intent to Treat EOS = End of Study Primary Analysis of ADHD-RS-5 based on MMRM (ITT Population)

SPN-812 P304 Phase III Topline Results Efficacy on 400 mg starting in week 2 Visit Statistics Placebo (N=96) 400 mg (N=99) 600 mg (N=97) Baseline Mean 38.8 41.2 39.8 Week 1 LS Mean -5.0 -6.7 -7.7 p-value 0.2460 0.0664 Week 2 LS Mean -7.8 -12.1 -10.9 p-value 0.0063 0.0456 Week 3 LS Mean -9.7 -14.7 -13.6 p-value 0.0035 0.0238 Week 4 LS Mean -11.7 -16.2 -13.8 p-value 0.0119 0.2423 Week 5 LS Mean -12.7 -17.2 -14.9 p-value 0.0100 0.1983 Week 6 LS Mean -13.5 -18.4 -16.8 p-value 0.0065 0.0690 Week 7 (EOS) LS Mean -13.2 -18.3 -16.7 p-value 0.0082 0.0712 9 MMRM = Mixed Model for Repeated Measure ITT = Intent to Treat EOS = End of Study

SPN-812 P304 Phase III Topline Results Visit Statistics Placebo (N=96) 400 mg (N=99) 600 mg (N=97) Baseline Mean 38.8 41.2 39.8 Week 7 (EOS) LS Mean -13.4 -17.9 -16.5 p-value 0.0191 0.1002 10 ANCOVA = Analysis of Covariance ITT = Intent to Treat EOS = End of Study Sensitivity Analysis of ADHD-RS-5 based on ANCOVA at Week 7 (EOS) Confirms Primary Analysis (ITT Population)

Visit Statistics Placebo (N=96) 400 mg (N=99) 600 mg (N=97) Baseline Mean 4.5 4.8 4.6 Week 7 (EOS) LS Mean 2.9 2.4 2.6 p-value 0.0051 0.0995 11 CGI-S was used as baseline; EOS = End of study Analysis of Observed Global Improvement Score (CGI-I) at Week 7 (EOS) SPN-812 P304 Phase III Topline Results

Visit Statistics Placebo (N=96) 400 mg (N=99) 600 mg (N=97) ADHD-RS-5 Hyperactivity/Impulsivity Baseline Mean 16.4 18.7 17.5 Week 7 (EOS) LS Mean -6.4 -8.3 -7.6 p-value 0.0484 0.2084 ADHD-RS-5 Inattention Baseline Mean 22.4 22.5 22.3 Week 7 (EOS) LS Mean -7.1 -10.1 -8.7 p-value 0.0042 0.1392 12 Analysis in ADHD-RS-5 Inattention and Hyperactivity/Impulsivity Subscales SPN-812 P304 Phase III Topline Results Significant Reduction in Hyperactivity and Inattention for 400 mg EOS = End of Study

13 Number (%) of Patients - Treatment Related AEs with > 5% incidence Placebo (N=97) 400 mg (N=100) 600 mg (N=99) Somnolence 3 (3.1) 13 (13.0) 17 (17.2) Fatigue 4 (4.1) 11 (11.0) 10 (10.1) Headache 3 (3.1) 9 (9.0) 7 (7.1) Decreased appetite 2 (2.1) 6 (6.0) 6 (6.1) Nausea 2 (2.1) 5 (5.0) 8 (8.1) Discontinuation due to AEs 1 (1.0) 4 (4.0) 5 (5.1) SPN-812 P304 Phase III Topline Results 400 mg and 600 mg Well Tolerated AEs = Adverse Events

SPN-812 Phase III Program Executive Summary Final Phase III data package for the NDA is robust on 100 mg, 200 mg and 400 mg doses in more than 1,000 children and adolescent patients. P304 Fourth Phase III trial Consistent with and confirms results from three successful Phase III trials (P301, P302 and P303) in children and adolescents Clinical data point to a well-differentiated ADHD product Strong efficacy with robust statistical significance Efficacy on both Hyperactivity/Impulsivity and Inattention Fast onset of action Very well tolerated Continue to target NDA submission 2H 2019, and if approved, launch 2H 2020 14

Growth Potential for Existing Products Potential Peak Sales for Oxtellar XR® and Trokendi XR® >$500M Innovative Late Stage Portfolio in Psychiatry SPN-812 Well Differentiated Novel Non-Stimulant SPN-810 First Product to be Developed for Impulsive Aggression SPN-604 Novel Product for Bipolar Disorder Positioned For Continued Strong Growth 15